Anti-bacterial compositions and uses thereof
AssigneePherecydes Pharma
InventorsCindy Fevre, Hélène Blois, Mathieu Medina
Life of this patent
Estimating the term…
Abstract
The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Staphylococcus aureus strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy and as companion diagnostic.
Claims17
An antibacterial composition comprising at least two distinct bacteriophages having lytic activity against at least one Staphylococcus aureus (S. aureus) strain and a pharmaceutically acceptable excipient or carrier,
- said at least two bacteriophages being selected from the bacteriophages having a genome comprising a nucleotide sequence of any one of SEQ ID NOs:
- 1 to 4 or a sequence having at least 95% identity thereto, and
- said pharmaceutically acceptable excipient or carrier comprising a preservative in an amount effective to preserve the activity of the bacteriophages.
A method of treating a Staphylococcus aureus (S. aureus) infection in a human or animal in need thereof, said method comprising administering to said human or animal an antibacterial composition in an amount effective to treat said infection, wherein said antibacterial composition comprises at least one bacteriophage having lytic activity against at least said S. aureus strain, said at least one bacteriophage being selected from the bacteriophages having a genome comprising a nucleotide sequence of any one of SEQ ID NOs:
- 1 to 4 or a sequence having at least 95% identity thereto.
A method of modifying the microbial flora in a human or animal to improve the condition of said human or animal, said method comprising administering to said human or animal an antibacterial composition in an amount effective to modify the microbial flora or to improve the condition, wherein said antibacterial composition comprises at least one bacteriophage having lytic activity against at least one Staphylococcus aureus (S. aureus) strain, said at least one bacteriophage being selected from bacteriophages having a genome comprising a nucleotide sequence of any one of SEQ ID NOs:
- 1 to 4 or a sequence having at least 95% identity thereto, and wherein said microbial flora comprises said S. aureus strain.
A method for decontaminating a material, said method comprising contacting said material with an antibacterial composition in an amount effective to decontaminate said material, wherein said antibacterial composition comprises at least one bacteriophage having lytic activity against at least one Staphylococcus aureus (S. aureus) strain, said at least one bacteriophage being selected from bacteriophages having a genome comprising a nucleotide sequence of any one of SEQ ID NOs:
- 1 to 4 or a sequence having at least 95% identity thereto, and wherein said material is contaminated with said S. aureus strain.
A method for preparing an antibacterial composition, said method comprising separately producing at least two bacteriophages having lytic activity against at least one Staphylococcus aureus (S. aureus) strain, said at least two bacteriophages being selected from bacteriophages having a genome comprising a nucleotide sequence of any one of SEQ ID NOs:
- 1 to 4 or a sequence having at least 95% identity thereto, and combining said bacteriophages with a suitable carrier or excipient.
A method for determining a cocktail of bacteriophages effective against a target Staphylococcus aureus (S. aureus) strain, comprising:
- a) separately contacting the target S. aureus strain, or a sample containing said strain, with (i) a bacteriophage having a genome comprising the nucleotide sequence of SEQ ID NO:
- 1 or a sequence having at least 95% identity thereto, and/or (ii) a bacteriophage having a genome comprising the nucleotide sequence of SEQ ID NO:
- 2 or a sequence having at least 95% identity thereto, and/or (iii) a bacteriophage having a genome comprising the nucleotide sequence of SEQ ID NO:
- 3 or a sequence having at least 95% identity thereto, and/or (iv) a bacteriophage having a genome comprising the nucleotide sequence of SEQ ID NO:
- 4 or a sequence having at least 95% identity thereto, and (v) one or more combinations thereof;
- b) selecting bacteriophages which exhibit lytic activity on the strain,
- c) optionally further selecting active bacteriophages which, when combined together, exhibit synergistic activity on the strain;
- and/or
- d) optionally further selecting active bacteriophages which, when combined together, exhibit no antagonism;
- and/or
- e) optionally selecting active bacteriophages which belong to different genus;
- and
- f) combining said selected bacteriophages.
Dependencies are inferred from the claim text.